Influence of Memantine on Continuous Treatment with Rivastigmine Patches<br/>—Retrospective Study Using the Logistic Regression Analysis—

DOI Web Site Web Site PubMed 13 References
  • Yasutaka Yuki
    Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Science, Fukuoka University Department of Hospital Pharmacy, Fukuoka University Hospital
  • Fujioka Shinsuke
    Department of Neurology, Faculty of Medicine, Fukuoka University
  • Terasawa Mariko
    Department of Hospital Pharmacy, Fukuoka University Hospital
  • Shibaguchi Hirotomo
    Department of Hospital Pharmacy, Fukuoka University Hospital Department of Biochemistry, Faculty of Medicine, Fukuoka University
  • Futagami Koujiro
    Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Science, Fukuoka University
  • Ouma Shinji
    Department of Neurology, Faculty of Medicine, Fukuoka University
  • Tsuboi Yoshio
    Department of Neurology, Faculty of Medicine, Fukuoka University
  • Kamimura Hidetoshi
    Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Science, Fukuoka University Department of Hospital Pharmacy, Fukuoka University Hospital

Bibliographic Information

Other Title
  • リバスチグミン貼付剤の投与継続に及ぼすメマンチンの影響<br/>—ロジスティック回帰分析を用いた後方視的研究—
  • リバスチグミン貼付剤の投与継続に及ぼすメマンチンの影響 : ロジスティック回帰分析を用いた後方視的研究
  • リバスチグミン チョウフザイ ノ トウヨ ケイゾク ニ オヨボス メマンチン ノ エイキョウ : ロジスティック カイキ ブンセキ オ モチイタ コウホウ シテキ ケンキュウ
  • Influence of Memantine on Continuous Treatment with Rivastigmine Patches<br/>&mdash;Retrospective Study Using the Logistic Regression Analysis&mdash;

Search this article

Abstract

 Rivastigmine patches exhibit stable effects when attached once a day, and may reduce Alzheimer's disease (AD) patient's or caregiver's burden. On the other hand, it was reported that adverse events, such as dermal disorder, frequently appeared after the start of rivastigmine administration. We retrospectively investigated medical records in 120 patients with moderate or mild AD in whom rivastigmine administration was started in the Department of Neurology, Fukuoka University Hospital between July 2011 and June 2014 (43 males, 77 females, mean age: 76.9±8.0 years). In 72 patients (60.0%), rivastigmine administration was discontinued within 52 weeks after its start. In 45 of these, it was discontinued before reaching a dose of 18 mg/d which was proven to be effective for AD patients. A primary reason for discontinuation was the appearance or deterioration of adverse events in 64 patients. Of these, 43 complained of dermal disorder, accounting for the highest percentage. To clarify factors influencing the continuous administration of rivastigmine, multivariate analysis was performed in 114 patients meeting criteria. Combination therapy with memantine was extracted as a factor (p=0.008). The results of this study suggest that adherence to combination therapy with rivastigmine and memantine is more favorable than that to monotherapy with rivastigmine.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 137 (1), 121-125, 2017

    The Pharmaceutical Society of Japan

References(13)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top